Merck Sharp + Dohme Corp.

Schering Corporation

Pharmacopeia Inc.

Pharmacopeia Drug Discovery, Inc.

Schering-Plough Corporation

Guoqing Li

Andrew William Stamford

Ying Huang

Ulrich Iserloh

Jared N Cumming

Zhaoning Zhu

Corey Strickland

William J Greenlee

Tao Guo

Yusheng Wu

Brian Alexander McKittrick

Lingyan Wang

Joseph A Kozlowski

Yongxin Han

Wensheng Yu

Elizabeth M Smith

Shuwen He

Liangqin Guo

Suresh D Babu

Robert D Mazzola, Jr

Alexander Pasternak

William K Hagmann

Kun Liu

Hongjun Zhang

Haifeng Tang

Fa-Xiang Ding

Yong Zhang

Jianmin Fu

Jing Su

Subharekha Raghavan

Hua Zhou

Ravi P Nargund

Robert G Aslanian

Michael D Altman

Xianhai Huang

Jack D Scott

Dong Xiao

Jongwon Lim

Derun Li

Michael Berlin

Jinlong Jiang

David L Sloman

Joey Lee Methot

Pauline C Ting

Sunil Paliwal

Deen Tulshian

Eric J Gilbert

Zhi-Cai Shi

Purakkattle J Biju

Douglas Walsh Hobbs

Xin Gu

Nunzio Sciammetta

Jianping Pan

Johannes H Voigt

Zhong-Yue Sun

Yuefei Shao

Gang Qian

Rui Zhang

Li Xiao

John P Caldwell

Kurt William Saionz

Yuanzan C Ye

Rachael Catherine Hunter

Xiaoxiang Liu

Michelle Lee Morris

Huizhong Gu

Gaifa Lai

Dawit Tadesse

Xavier Fradera

Haiqun Tang

Abdelghani Achab

Shuzhi Dong

Cameron James Smith

Shouwu Miao

Yi-Heng Chen

Dane James Clausen

Qinglin Pu

Weidong Pan

Thuy X H Le

Dexi Yang

John E Stelmach

Mihir Mandal

Shu-Wei Yang

Alan Whitehead

Joie Garfunkle

Ping Chen

Yongqi Deng

Junying Zheng

Clare London

John W Lampe

Ginny Dai Ho

Zhiqiang Zhao

Jacqueline D Hicks

Walter Won

Yuhua Huang

Hong Li

Feng Ye

Liang Zhu

Mihirbaran Mandal

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted N'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: 'Z', Rand Rare defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Aminopyrazine compounds with A2A antagonist properties

The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R, R, R, R, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate ('cGMP'), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

Soluble guanylate cyclase stimulators

The present invention relates to compounds of formula I that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors

The present invention relates to compounds of formula (I) that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

Metallo-beta-lactamase inhibitors

The present invention relates to inhibitors of IRAK4 of Formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

Inhibitors of IRAK4 activity

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): 

Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein

Preparation and use of compounds as protease inhibitors

This invention relates to amidopyrazole compounds that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment of cellular proliferative diseases, for example, cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation.

Amidopyrazole inhibitors of interleukin receptor-associated kinases

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic magonist or mantagonist.

Heterocyclic aspartyl protease inhibitors

Substituted isoindolines as aspartyl protease inhibitors

Growing community of inventors

Belle Mead, NJ, United States of America

Guoqing Li